Pancreatic Cancer Research

ResearcherNagoya City UniversityActive in the last 2 years

Tomokatsu Kato

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109517780. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 10

  1. Interleukin-1 receptor type 1 in pancreatic cancer progression and metastasis: a review. Co-author DOI 10.1007/s10147-026-03000-7↗
  2. The Natural Compound CalebinA Suppresses Gemcitabine Resistance and Tumor Progression by Inhibiting Angiogenesis and Invasion Through NF-κB Signaling in Pancre… Co-author DOI 10.3390/nu17162641↗
  3. Expression of ZKSCAN3 protein suppresses proliferation, migration, and invasion of pancreatic cancer through autophagy. Co-author DOI 10.1111/cas.16173↗
  4. The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in… Co-author DOI 10.3390/nu16050705↗
  5. Clinical Outcomes of Intraoperative Radiotherapy, Postoperative Radiotherapy, and Definitive Radiotherapy for Non-metastatic Pancreatic Cancer. Co-author DOI 10.2739/kurumemedj.ms674002↗
  6. Upregulation of integrin‑linked kinase enhances tumor progression in gemcitabine‑resistant pancreatic cancer. Co-author DOI 10.3892/or.2023.8601↗
  7. Girdin regulates both migration and angiogenesis in pancreatic cancer cell lines. Co-author DOI 10.3892/or.2023.8606↗
  8. 10Z‑Hymenialdisine inhibits angiogenesis by suppressing NF‑κB activation in pancreatic cancer cell lines. Co-author DOI 10.3892/or.2022.8259↗
  9. Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiation‑resistant pancreatic cancer. Co-author DOI 10.3892/or.2022.8279↗
  10. Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreat… Co-author DOI 10.3892/or.2021.8006↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoichi Matsuo · 10 shared papers, 2021–2026 · strength 1.70
  2. Shuji Takiguchi · 9 shared papers, 2021–2026 · strength 1.53
  3. Kenta Saito · 9 shared papers, 2021–2026 · strength 1.53
  4. Hiromichi Murase · 8 shared papers, 2022–2026 · strength 1.41
  5. Hiroki Takahashi · 8 shared papers, 2021–2025 · strength 1.25
  6. Keisuke Nonoyama · 6 shared papers, 2023–2026 · strength 1.14
  7. Yuki Denda · 6 shared papers, 2023–2026 · strength 1.14
  8. Hiroyuki Imafuji · 7 shared papers, 2021–2024 · strength 1.04
  9. Mamoru Morimoto · 7 shared papers, 2021–2024 · strength 1.04
  10. Yuichi Hayashi · 5 shared papers, 2021–2023 · strength 0.68
  11. Saburo Sugita · 3 shared papers, 2024–2025 · strength 0.57
  12. Yuki Eguchi · 3 shared papers, 2024–2025 · strength 0.57
  13. Kan Omi · 4 shared papers, 2021–2023 · strength 0.53
  14. Goro Ueda · 4 shared papers, 2021–2023 · strength 0.53
  15. Takeshi Yanagi · 1 shared paper, 2023 · strength 0.18
  16. Yuta Shibamoto · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.